Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
AstraZeneca
Dow
Express Scripts
Moodys

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR ALPHANATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for ALPHANATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00323856 ↗ Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A Active, not recruiting Grifols Biologicals Inc. Phase 4 2003-01-01 The purpose of this study is to determine the immunologic and overall safety associated with long-term use of Alphanate in subjects diagnosed with severe hemophilia A (Factor VIII:C less than 0.01 IU/ml), who have been previously treated with plasma-derived Factor VIII products other than Alphanate and who have no history of developing either antibody inhibitors to Factor VIII or nonspecific inhibitors of coagulation.
NCT00323856 ↗ Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A Active, not recruiting Grifols Biologicals, LLC Phase 4 2003-01-01 The purpose of this study is to determine the immunologic and overall safety associated with long-term use of Alphanate in subjects diagnosed with severe hemophilia A (Factor VIII:C less than 0.01 IU/ml), who have been previously treated with plasma-derived Factor VIII products other than Alphanate and who have no history of developing either antibody inhibitors to Factor VIII or nonspecific inhibitors of coagulation.
NCT01051076 ↗ Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) Completed Biotest Pharmaceuticals Corporation N/A 2009-11-03 The purpose of this study is to evaluate whether a concentrate containing both FVIII and von Willebrand Factor (VWF) given at a high dose will induce immune tolerance in subjects who have already experienced and failed ITI with VWF-free FVIII concentrates. The treatment on this study is expected to last up to 33 months.
NCT01051076 ↗ Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) Completed Charta Fondazione N/A 2009-11-03 The purpose of this study is to evaluate whether a concentrate containing both FVIII and von Willebrand Factor (VWF) given at a high dose will induce immune tolerance in subjects who have already experienced and failed ITI with VWF-free FVIII concentrates. The treatment on this study is expected to last up to 33 months.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ALPHANATE

Condition Name

Condition Name for ALPHANATE
Intervention Trials
Severe Hemophilia A 3
Hemophilia A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ALPHANATE
Intervention Trials
Hemophilia A 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ALPHANATE

Trials by Country

Trials by Country for ALPHANATE
Location Trials
United States 13
Poland 2
Argentina 2
Turkey 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ALPHANATE
Location Trials
California 3
Texas 2
North Dakota 1
Nevada 1
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ALPHANATE

Clinical Trial Phase

Clinical Trial Phase for ALPHANATE
Clinical Trial Phase Trials
Phase 4 2
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ALPHANATE
Clinical Trial Phase Trials
Completed 2
Withdrawn 1
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ALPHANATE

Sponsor Name

Sponsor Name for ALPHANATE
Sponsor Trials
Grifols Biologicals Inc. 3
Grifols Biologicals, LLC 3
Grifols Therapeutics LLC 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ALPHANATE
Sponsor Trials
Industry 15
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Baxter
Express Scripts
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.